专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

AU2006274834A8 Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives 未知
公开(公告)号：AU2006274834A8
公开(公告)日：2008-07-17
申请号：AU2006274834
申请日：2006-07-27
申请人： BOEHRINGER INGELHEIM INT , AJINOMOTO KK
发明人： EICKELMANN PETER , BARSOUMIAN EDWARD LEON , HIMMELSBACH FRANK , THOMAS LEO , MAEZONO KATSUMI , OHSUMI KOJI , STREICHER RUEDIGER , HATANAKA TOSHIHIRO , PINNETTI SABINE , DUGI KLAUS , ISHIDA NOZOMU , RITTER REGINE , MAIER ROLAND , FUJITA KOICHI
IPC分类号： A61K31/7056 , A61P3/04 , A61P3/10 , C07H17/02
摘要： The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

32. 发明专利

CA2669043A1 COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS 未知
公开(公告)号：CA2669043A1
公开(公告)日：2008-05-15
申请号：CA2669043
申请日：2007-11-08
申请人： BOEHRINGER INGELHEIM INT
发明人： MANUCHEHRI ALIREZA , THOMAS LEO , DUGI KLAUS , EICKELMANN PETER
IPC分类号： A61K31/341 , A61K31/70 , A61P3/00 , A61P3/10
摘要： The present invention is directed to a pharmaceutical composition compris ed of one or more SGLT-2 inhibitor compound(s) in combination with one or mo re therapeutic agents which is suitable for the treatment of metabolic disor ders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, ob esity, including class I obesity, class II obesity, class III obesity, visce ral obesity and abdominal obesity, and metabolic syndrome.

33. 发明专利

CA2833705A1 USE OF DPP IV INHIBITORS 未知
公开(公告)号：CA2833705A1
公开(公告)日：2007-11-15
申请号：CA2833705
申请日：2007-05-03
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , HIMMELSBACH FRANK , MARK MICHAEL
IPC分类号： A61K31/522 , A61K31/5025 , A61P9/04
摘要： Use of dipeptidyl peptidase IV inhibitor compound (A) of (I) or (II) and/or their salts for the preparation of medicament to treat a patient with physiological functional disorders such as pre-diabetes, glucose-intolerance, pathological fasting-glucose, diabetic foot, diabetes associated ulcer, diabetic hyperlipidemia, diabetic dyslipidemia, newly diagnosed type 1 diabetes, gestation-diabetes, hyperglycemia, adrenergic postprandial syndrome and cardiac insufficiency, or for therapeutic treatment of a patient with transplanted islet langerhans or beta cell. Use of dipeptidyl peptidase IV inhibitor (A) compound of formula (I) or (II) and/or their salts for the preparation of medicament to treat a patient with physiological functional disorders such as pre-diabetes, glucose-intolerance, pathological fasting-glucose, diabetic foot, diabetes associated ulcer, diabetic hyperlipidemia, diabetic dyslipidemia, newly diagnosed type 1 diabetes, gestation-diabetes, hyperglycemia, adrenergic postprandial syndrome and cardiac insufficiency, or for therapeutic treatment of a patient with transplanted islet langerhans or beta cell. R1 : ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl, (quinoxalin-6-yl) methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl or (4,6-dimethyl-pyrimidin-2-yl)methyl; and R2 : 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamine or (2-(S)-amino-propyl)-methylamine. Independent claims are included for: (1) isolation or storage medium for islet langerhans or beta cell, where the medium strengthens vitality and secretion capacity of the cell 1 nmol/l to 1 mu mol/l of (I); and (2) a procedure for strengthening the vitality and secretion capacity of islet langerhans or beta cells comprising adding (I) in a concentration of 1 nmol/l to 1 mu mol/l to the isolation medium or storage medium during the isolation and transplantation phase of the islet langerhans or beta -cells. [Image] ACTIVITY : Antidiabetic; Metabolic; Antiulcer; Dermatological; Antilipemic; Cardiant; Vasotropic; Antianginal; Cardiovascular-Gen; Antiarrhythmic. MECHANISM OF ACTION : Dipeptidyl peptidase IV inhibitor.

34. 发明专利

UY29694A1 METODOS PARA PREVENIR Y TRATAR TRASTORNOS METABOLICOS Y NUEVOS DERIVADOS DE PIRAZOL-O-GLUCOSIDO 未知
公开(公告)号：UY29694A1
公开(公告)日：2007-02-28
申请号：UY29694
申请日：2006-07-24
申请人： BOEHRINGER INGELHEIM INT
发明人： HIMMELSBACH FRANK , MAIER ROLAND , THOMAS LEO , EICKELMANN PETER , BARSOUMIAN EDWARD LEON , DUGI KLAUS , BRAVO SABINE QUISPE , RITTER REGINE , STREICHER RUDIGER , FUJITA KOICHI , HATANAKA TOSHIHIRO , ISHIDA NOZOMU , MAEZONO KATSUMI , OHSUMI KOJI
IPC分类号： A61K31/4155 , A61P3/00 , C07D231/20 , C07H17/02
摘要： Métodos para : prevenir/tratar trastornos metabólicos, mejorar el control glucémico, prevenir la progresión desde la tolerancia alterada a la glucosa, la resitencia a la insulina y/o desde el síndrome metabólico hasta la diabetes mellitus de tipo 2, prevenir/tratar las complicaciones de la diabetes mellitus, reducir el peso, prevenir/tratar la degeneración de las células beta pancreáticas, tratar hiperinsulinemia y resistencia a la insulina y diabetes de tipo 1, en pacientes que lo necesiten, mediante administración de composición farmacéutica que comprende pirazol-O-glucósido como se define en la reivindicación 1, o su profármaco, o su sal farmacéuticamente aceptable.

35. 发明专利

EA036618B1 СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ ВЫРАЖЕННОГО ДИАБЕТА 2 ТИПА С ПОМОЩЬЮ ИНГИБИТОРА DPP IV 未知
公开(公告)号：EA036618B1
公开(公告)日：2020-11-30
申请号：EA201300213
申请日：2007-05-03
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , HIMMELSBACH FRANK , MARK MICHAEL
IPC分类号： A61K31/522 , A61K31/4985 , A61P3/10 , A61P9/04
摘要： Изобретениеотноситсяк способамтерапевтическоголечениявыраженногодиабета 2 типа, включающимпероральноевведениепациентуингибитора DPP IV формулы (I), где R1 обозначает (4-метилхиназолин-2-ил)метили R2 обозначает 3-(R)-аминопиперидин-1-ил, илиегосолив суточнойдозировке 5 мг, необязательнов комбинациис метформином. Изобретениетакжеотноситсяк лекарственнойкомбинации, содержащей, 2,5 или 5 мгуказанногоингибитора DPP IV формулы (I) илиегосоли, дляпероральноговведениясуточнойдозировки 5 мги метформин. Соединениеформулы (I)

36. 发明专利

ES2760917T3 Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina 未知
公开(公告)号：ES2760917T3
公开(公告)日：2020-05-18
申请号：ES10785054
申请日：2010-11-26
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , GRAEFE-MODY EVA , MARK MICHAEL , WOERLE HANS-JUERGEN , ZIMDAHL-GELLING HEIKE
IPC分类号： A61K31/155 , A61K31/44 , A61K31/519 , A61K45/06 , A61P3/10
摘要： Un compuesto farmacéutico, composición o combinación que comprende (a) un inhibidor 5 de DPP-4, que es linagliptina, o una sal farmacéuticamente aceptable del mismo, y, opcionalmente, (b) un segundo agente antidiabético seleccionado del grupo G3 que consiste en biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, análogos de GLP-1 o GLP-1, y análogos de insulina o insulina, y, opcionalmente, (c) un tercer agente antidiabético diferente de (b) seleccionado del grupo G3 que consiste en biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, análogos de GLP-1 o GLP-1, y análogos de insulina o insulina, o una sal farmacéuticamente aceptable del mismo; para uso en el tratamiento de la diabetes mellitus tipo 2, dicho uso comprende probar que el paciente tiene al menos un alelo T en el polimorfismo de un solo nucleótido (SNP) rs7903146 en el gen que codifica TCF7L2, y administrar el compuesto farmacéutico, composición o combinación al paciente.

37. 发明专利

MY170728A TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY 未知
公开(公告)号：MY170728A
公开(公告)日：2019-08-27
申请号：MYPI2014001092
申请日：2009-08-05
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , GRAEFE-MODY EVA ULRIKE , HARPER RUTH , WOERLE HANS-JUERGEN
摘要： The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin. (No suitable figure)

38. 发明专利

HRP20170022T1 FARMACEUTSKI SASTAV KOJI OBUHVAĆA DERIVAT BENZENA SUPSTITUIRAN GLUKOPIRANOZILOM 未知
公开(公告)号：HRP20170022T1
公开(公告)日：2017-03-10
申请号：HRP20170022
申请日：2017-01-09
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , MARK MICHAEL , THOMAS LEO , HIMMELSBACH FRANK
IPC分类号： A61K31/00 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/70 , A61K31/7034 , A61P3/04 , A61P3/06 , A61P3/10

39. 发明专利

CY1115350T1 ΧΡΗΣΕΙΣ ΑΝΑΣΤΟΛΕΩΝ ΤΗΣ DPP IV 未知
公开(公告)号：CY1115350T1
公开(公告)日：2017-01-04
申请号：CY141100508
申请日：2014-07-07
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , HIMMELSBACH FRANK , MARK MICHAEL
IPC分类号： A61K31/522 , A61K31/4985 , A61P3/10 , A61P9/04
摘要： Περιγράφεταιη χρήσηεπιλεγμένωναναστολέωντης DPP IV γιατηναντιμετώπισηφυσιολογικώνλειτουργικώνδιαταραχών, καθώςκαιγιατηνμείωσητουκινδύνουεμφάνισηςτέτοιωνλειτουργικώνδιαταραχώνσεευπαθείςομάδεςασθενών. Επιπλέονπεριγράφεταιη χρήσητωναναφερόμενωναναστολέωντης DPP IV σεσυνδυασμόμεάλλεςδραστικέςουσίες, έτσιώστεμπορούνναεπιτευχθούνβελτιωμέναθεραπευτικάαποτελέσματα. Οιχρήσειςαυτέςμπορούνναχρησιμεύσουνγιατηνπαραγωγήφαρμάκων.

40. 发明专利

CA2875706C USE OF DPP IV INHIBITORS 未知
公开(公告)号：CA2875706C
公开(公告)日：2016-07-26
申请号：CA2875706
申请日：2007-05-03
申请人： BOEHRINGER INGELHEIM INT
发明人： DUGI KLAUS , HIMMELSBACH FRANK , MARK MICHAEL
IPC分类号： A61K31/522 , A61K31/155 , A61K31/4184 , A61K31/4439
摘要： Disclosed is the use of selected DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders. Also disclosed is the use of said DPP-IV inhibitors in combination with other agents such that improved treatment results can be obtained. Said uses can be employed for producing corresponding medicaments.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式